Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus UTICILLIN VK.
LAROTID vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic